NeuroSense Therapeutics Ltd.

NasdaqCM NRSN

NeuroSense Therapeutics Ltd. EBITDA for the year ending December 31, 2023: USD -10.63 M

NeuroSense Therapeutics Ltd. EBITDA is USD -10.63 M for the year ending December 31, 2023, a 20.52% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

NeuroSense Therapeutics Ltd. EBITDA for the year ending December 31, 2022 was USD -13.38 M, a -363.90% change year over year.
NeuroSense Therapeutics Ltd. EBITDA for the year ending December 31, 2021 was USD -2.88 M, a -2.09% change year over year.
NeuroSense Therapeutics Ltd. EBITDA for the year ending December 31, 2020 was USD -2.83 M, a -125.46% change year over year.
NeuroSense Therapeutics Ltd. EBITDA for the year ending December 31, 2019 was USD -1.25 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: NRSN

NeuroSense Therapeutics Ltd.

CEO	Mr. Alon Ben-Noon
IPO Date	Dec. 9, 2021
Location	Israel
Headquarters	Building B
Employees	18
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Key trends

Past 5 years